Table 1

Distribution of the PTEN polymorphism and the relative risk of prostate cancer

PTEN GenotypeNo insertionHeterozygousInsertion
Overall
 No. cases (%)262 (43.7)281 (46.8)57 (9.5)
 No. controls (%)346 (43.1)367 (45.7)90 (11.2)
 RR (95% CI)1.00 (reference)1.01 (0.81–1.27)0.86 (0.59–1.24)
Low-risk PCa
 No. cases/controls133/176119/17433/41
 RR (95% CI)1.00 (reference)0.91 (0.66–1.26)1.09 (0.65–1.82)
High-risk PCa
 No. cases/controls112/148136/17719/43
 RR (95% CI)1.00 (reference)1.01 (0.72–1.41)0.59 (0.32–1.07)
Gleason <7
 No. cases/controls123/163116/17129/37
 RR (95% CI)1.00 (reference)0.90 (0.65–1.26)1.07 (0.62–1.84)
Gleason ≥7
 No. cases/controls62/8886/9411/26
 RR (95% CI)1.00 (reference)1.27 (0.81–1.97)0.59 (0.27–1.29)
Stage AB
 No. cases/controls186/245193/24744/56
 RR (95% CI)1.00 (reference)1.03 (0.79–1.35)1.07 (0.69–1.66)
Stage CD
 No. cases/controls76/10188/12013/34
 RR (95% CI)1.00 (reference)0.98 (0.65–1.47)0.51 (0.25–1.03)